CDK12 variants were investigated as a genetic susceptibility to ovarian cancer in a series of 416 unrelated and consecutive patients with ovarian carcinoma and who carry neither germline BRCA1 nor BRCA2 pathogenic variant. The presence of CDK12 variants was searched in germline DNA by massive parallel sequencing on pooled DNAs. The lack of detection of deleterious variants and the observed proportion of missense variants in the series of ovarian carcinoma patients as compared with all human populations strongly suggests that CDK12 is not an ovarian cancer predisposing gene.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Lheureux S, Gourley C, Vergote I, Oza AM (2019) Epithelial ovarian cancer. Lancet 393:1240–1253. https://doi.org/10.1016/S0140-6736(18)32552-2
Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402–2416. https://doi.org/10.1001/jama.2017.7112
Golmard L, Castera L, Krieger S et al (2017) Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers. Eur J Hum Genet 25:1345–1353. https://doi.org/10.1038/s41431-017-0021-2
Loveday C, Turnbull C, Ramsay E et al (2011) Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 43:879–882. https://doi.org/10.1038/ng.893
Loveday C, Turnbull C, Ruark E, et al. (2012) Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 44:475–476; author reply 6 https://doi.org/10.1038/ng.2224
Bewtra C, Watson P, Conway T, Read-Hippee C, Lynch HT (1992) Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol 11:180–187
Helder-Woolderink JM, Blok EA, Vasen HF, Hollema H, Mourits MJ, De Bock GH (2016) Ovarian cancer in Lynch syndrome; a systematic review. Eur J Cancer 55:65–73. https://doi.org/10.1016/j.ejca.2015.12.005
Bonadona V, Bonaiti B, Olschwang S et al (2011) Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305:2304–2310. https://doi.org/10.1001/jama.2011.743
Wu YM, Cieslik M, Lonigro RJ et al (2018) Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173(1770–82):e14. https://doi.org/10.1016/j.cell.2018.04.034
Popova T, Manie E, Boeva V et al (2016) Ovarian cancers harboring inactivating mutations in CDK12 display a distinct genomic instability pattern characterized by large tandem duplications. Cancer Res 76:1882–1891. https://doi.org/10.1158/0008-5472.CAN-15-2128
Juan HC, Lin Y, Chen HR, Fann MJ (2016) Cdk12 is essential for embryonic development and the maintenance of genomic stability. Cell Death Differ 23:1038–1048. https://doi.org/10.1038/cdd.2015.157
Blazek D, Kohoutek J, Bartholomeeusen K et al (2011) The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev 25:2158–2172. https://doi.org/10.1101/gad.16962311
Bajrami I, Frankum JR, Konde A et al (2014) Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res 74:287–297. https://doi.org/10.1158/0008-5472.CAN-13-2541
Tien JF, Mazloomian A, Cheng SG et al (2017) CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion. Nucleic Acids Res 45:6698–6716. https://doi.org/10.1093/nar/gkx187
Krajewska M, Dries R, Grassetti AV et al (2019) CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat Commun 10:1757. https://doi.org/10.1038/s41467-019-09703-y
Dubbury SJ, Boutz PL, Sharp PA (2018) CDK12 regulates DNA repair genes by suppressing intronic polyadenylation. Nature 564:141–145. https://doi.org/10.1038/s41586-018-0758-y
Choi SH, Martinez TF, Kim S et al (2019) CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability. Genes Dev 33:418–435. https://doi.org/10.1101/gad.322339.118
Au CH, Ho DN, Kwong A, Chan TL, Ma ESK (2017) BAMClipper: removing primers from alignments to minimize false-negative mutations in amplicon next-generation sequencing. Sci Rep 7:1567. https://doi.org/10.1038/s41598-017-01703-6
DePristo MA, Banks E, Poplin R et al (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43:491–498. https://doi.org/10.1038/ng.806
Li H, Handsaker B, Wysoker A et al (2009) The sequence alignment/map format and SAMtools. Bioinformatics 25:2078–2079. https://doi.org/10.1093/bioinformatics/btp352
Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38:e164
Yeo G, Burge CB (2004) Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol 11:377–394. https://doi.org/10.1089/1066527041410418
Boeva V, Popova T, Bleakley K et al (2012) Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics 28:423–425. https://doi.org/10.1093/bioinformatics/btr670
Lek M, Karczewski KJ, Minikel EV et al (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285–291. https://doi.org/10.1038/nature19057
Brovkina OI, Shigapova L, Chudakova DA et al (2018) The ethnic-specific spectrum of germline nucleotide variants in dna damage response and repair genes in hereditary breast and ovarian cancer patients of tatar descent. Front Oncol 8:421. https://doi.org/10.3389/fonc.2018.00421
Bogdanova NV, Schurmann P, Valova Y et al (2019) A splice site variant of CDK12 and breast cancer in three Eurasian populations. Front Oncol 9:493. https://doi.org/10.3389/fonc.2019.00493
Pan L, Xie W, Li KL et al (2015) Heterochromatin remodeling by CDK12 contributes to learning in Drosophila. Proc Natl Acad Sci USA 112:13988–13993. https://doi.org/10.1073/pnas.1502943112
Supported by the Institut National de la Santé et de la Recherche Médicale (INSERM) and the Institut Curie. M. S-G and A. E. are supported by fellowships from the Université de Rouen and the Ligue Nationale Contre le Cancer, respectively. The Institut Curie ICGex NGS platform is funded by the EQUIPEX investissements d’avenir program (ANR-10-EQPX-03) and ANR10-INBS-09-08 from the Agence Nationale de la Recherche. We thank the patients. We also acknowledge support from the Institut Curie for sample collection, banking and processing: the Biological Resource Center and its members (O. Mariani).
Conflict of interest
E. Manié, T. Popova and M.-H. Stern are named inventors of a patent licensed to Myriad Genetics. No potential conflicts of interest were disclosed by the other authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Eeckhoutte, A., Saint-Ghislain, M., Reverdy, M. et al. Lack of evidence for CDK12 as an ovarian cancer predisposing gene. Familial Cancer 19, 203–209 (2020). https://doi.org/10.1007/s10689-020-00169-2
- Cancer susceptibility
- Ovarian carcinoma
- Pool sequencing